# Junta clínica — PT-pseudo_a2ed5cd06259 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_a2ed5cd06259",
  "pid": "PT-pseudo_a2ed5cd06259",
  "task": 1,
  "psa": 4.6,
  "age": 76,
  "months": 3,
  "pirads": "5",
  "psad": 0.153,
  "psav": 0.81,
  "psap": 3.4,
  "vol": 30.02,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8208632,
  "medhx": "Type 2 diabetes",
  "meds": "empagliflozin",
  "notes": "PSA 4.6 ng/mL. PI-RADS 5. PSAD 0.15. Prostate volume 30 mL. csPCa 0.82.",
  "pmhx": [
    "Type 2 diabetes"
  ],
  "allergies": [],
  "vitals": {
    "weight": "103 kg",
    "height": "193 cm",
    "bmi": "27.7",
    "bp": "137/83 mmHg",
    "hr": "65 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "10 Jan 2025",
  "enc_ref": "Dr. T. Hendriks (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending PSA values combined with a previously positive biopsy require specialist re-evaluation."
    },
    {
      "s": "History",
      "t": "A 76-year-old non-smoker initially entered evaluation due to a late-2023 PSA elevation. Later, a systematic biopsy confirmed low-grade disease. Type 2 diabetes is managed using empagliflozin. An IPSS score of 2 points to negligible urinary symptom bother. Formerly a police officer, he is divorced and resides with his partner. Weekends feature hiking trips. Alcohol remains capped at 13 units weekly. Orthopaedic follow-ups address a chronic knee issue. Podiatry visits handle foot maintenance. An Arabic interpreter has been requested. Bone pain, haematuria, and unexplained weight loss are denied. Overall wellness stays steady."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Texture is uniformly smooth. Dimensions are symmetric. No nodularity. No asymmetry. General inspection shows a well-nourished individual appearing comfortable. Vital signs remain stable. Cardiopulmonary assessment is normal."
    }
  ],
  "occupation": "retired police officer",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Orthopaedic outpatient — knee follow-up",
    "Podiatry — routine foot care"
  ],
  "alcohol": "13 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 2/35 (mild LUTS)",
  "admin": "Interpreter (Arabic) requested for next visit.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_a2ed5cd06259
Task: 1

Encounter: Urology - outpatient on 10 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 76-year-old male
  - PSA: 4.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.153 ng/mL²
  - PSA velocity: 0.81 ng/mL/yr
  - Prior PSA: 3.4 ng/mL
  - Prostate volume: 30.02 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8208632 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes
  - Problem list / PMHx: Type 2 diabetes
  - Current medication: empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 4.6 ng/mL. PI-RADS 5. PSAD 0.15. Prostate volume 30 mL. csPCa 0.82.

Vitals: weight 103 kg, height 193 cm, BMI 27.7, BP 137/83 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Ascending PSA values combined with a previously positive biopsy require specialist re-evaluation.

History: A 76-year-old non-smoker initially entered evaluation due to a late-2023 PSA elevation. Later, a systematic biopsy confirmed low-grade disease. Type 2 diabetes is managed using empagliflozin. An IPSS score of 2 points to negligible urinary symptom bother. Formerly a police officer, he is divorced and resides with his partner. Weekends feature hiking trips. Alcohol remains capped at 13 units weekly. Orthopaedic follow-ups address a chronic knee issue. Podiatry visits handle foot maintenance. An Arabic interpreter has been requested. Bone pain, haematuria, and unexplained weight loss are denied. Overall wellness stays steady.

Physical examination: DRE: Texture is uniformly smooth. Dimensions are symmetric. No nodularity. No asymmetry. General inspection shows a well-nourished individual appearing comfortable. Vital signs remain stable. Cardiopulmonary assessment is normal.

Patient info: retired police officer; Divorced; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 13 units / week; exercise Hiking on weekends; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up; Podiatry — routine foot care.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.10 epistemic (95% band 0.37-0.76); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.94: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  2. distance 1.15: PI-RADS 5, PSA 10.0, PSAD 0.27, age 75, DRE Normal -> BIOPSY (clear). He wrote: "New(? -> no old MRI report included) PIRADS 5 and rising PSA makes biopsy necessary"
  3. distance 1.31: PI-RADS 5, PSA 10.0, PSAD 0.372, age 75, DRE Normal -> BIOPSY (clear). He wrote: "Intermediate risk disease in 75yr with some comorbidity. No targeted biopsy and unclear timing (when was diagnosis and prev biopsy). Unclear if PIRADS5 was biopsied (lim…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings and the PSA density. The panel variables alone do not settle the issue when the guideline suggests that a stable MRI (PRECISE 1-3) might exclude a repeat biopsy.

WHAT WE STILL NEED
The guideline requires information on the MRI findings to determine if a repeat biopsy is warranted.
Prior biopsy status is documented as "Positive," which is a fact that the guideline makes decisive.
The panel shows PI-RADS 5, which is a fact that the guideline makes decisive.
The panel shows PSA 4.6 ng/mL, which is a fact that the guideline makes decisive.
The panel shows PSA density 0.153 ng/mL², which is a fact that the guideline makes decisive.
The panel shows prostate volume 30.02 mL, which is a fact that the guideline makes decisive.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the grade of the prior biopsy and the surveillance plan documented in the previous notes, as the panel variables alone are insufficient.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the prior biopsy finding (Gleason/ISUP), the number and dates of biopsy sessions, and the surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI Prostate
Date: 08 Jan 2025
Department: Amsterdam UMC (location AMC)
Clinical indication: Re-evaluation for rising PSA (4.6 ng/mL) and prior positive biopsy.
FINDINGS:
The gland measures 30.02 mL in volume. T2-weighted sequences reveal a focal hypointense area within the right anterior mid-gland zone, spanning roughly 12 x 10 mm. Diffusion-weighted imaging shows pronounced signal restriction alongside corresponding low ADC values. Dynamic contrast-enhanced sequences highlight early, focal enhancement in this region. The peripheral zone otherwise appears normal. Seminal vesicles remain intact. There is no extraprostatic extension nor suspicious pelvic lymphadenopathy.
IMPRESSION:
PI-RADS 5 lesion in the right anterior mid-gland.
Prostate volume 30.02 mL; PSA density 0.153 ng/mL/mL.
csPCa predicted probability 0.8208632.
COMPARISON: new

psa_trend
{"date": "Dec 2023", "val": 0.7}, {"date": "Mar 2024", "val": 1.2}, {"date": "Jun 2024", "val": 0.5}, {"date": "Oct 2024", "val": 1.9}, {"date": "Jan 2025", "val": 4.6}
What is the serial PSA value trend (rising, flat, or falling)? The serial PSA value trend is rising, with the latest value being 4.6 ng/mL in Jan 2025.

previous_notes
{"date": "21 Jan 2023", "author": "Dr. T. Hendriks (GP)", "text": "Initial PSA screening in January 2023 measured 2.1 ng/mL. Following the patient's age and mild lower urinary tract symptoms, a repeat test was scheduled for the subsequent winter. Later evaluations in December 2023 and March 2024 yielded 2.2 and 2.3 ng/mL, respectively. Urology referral followed the most recent PSA reading of 4.6 ng/mL alongside previous biopsy results."}
What was the prior biopsy finding (Gleason/ISUP), the number and dates of biopsy sessions, and the surveillance protocol status? The prior biopsy finding is not explicitly stated as Gleason/ISUP, but the notes mention "previous biopsy results." The number and dates of biopsy sessions are not specified, and the surveillance protocol status is not specified.

laboratory_results
{"name": "PSA", "val": "4.6 ng/mL", "date": "25 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.48 ng/mL", "date": "25 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "11%", "date": "25 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "13.9 g/dL", "date": "25 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.4 x10^9/L", "date": "25 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "271 x10^9/L", "date": "25 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "93 umol/L", "date": "25 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "25 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "9.7 nmol/L", "date": "25 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "89 U/L", "date": "25 Dec 2024", "flag": ""}, {"name": "LDH", "val": "163 U/L", "date": "25 Dec 2024", "flag": "H"}
What are the full panel results, including free-PSA fraction, renal function, and haemoglobin? The Free PSA fraction is 11%, renal function is eGFR >60 mL/min/1.73m2, and Haemoglobin is 13.9 g/dL.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already mentioned the context of the prior biopsy.

WHAT THIS SUPPORTS
findings that

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.60 ng/mL over 5 points spanning 13 months; velocity +3.13 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 7.0 ng/mL, conformal 95% band 2.0-24.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.10 epistemic (95% band 0.34-0.72), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.57  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.53  ('discuss' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.62 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—address the moderator's questions to some extent. The laboratory results provide PSA and Free PSA data, and the MRI report provides imaging characteristics. However, the specific documented grade (Gleason/ISUP) of the prior biopsy and the status of the surveillance protocol are not explicitly stated in the retrieved reports.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY recommendation based on a weighted vote, noting that the documented prior grade was "none recorded" in the opened documents. The retrieved evidence does not contradict the panel's reliance on the trained experts when key historical data is absent.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? This remains unanswered by the retrieved documents.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? This remains unanswered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables for the EAU guideline are the MRI findings (PI-RADS 5) and the PSA density (0.153 ng/mL/mL), as the guideline suggests a stable MRI might exclude a repeat biopsy. The prior biopsy status and surveillance plan are critical because the panel protocol explicitly stated that the decision rested on these factors, which were not retrieved.

MY SUGGESTION TO THE CHAIR
Given that the critical information regarding the prior biopsy grade and surveillance status is missing from the retrieved documents, the decision cannot be definitively made according to the panel protocol. The record is not ready for a final decision based on the retrieved evidence alone.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

A repeat biopsy is indicated because the patient has a PI-RADS 5 lesion and a rising PSA trend, with the latest value being 4.6 ng/mL in January 2025. The decision was driven by the weighted vote of experts, where the fusion classifier carried the most weight, as the retrieved documents did not explicitly document the prior biopsy grade or surveillance status. The evidence converged on the need for further histological confirmation.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
